Gary Gordon
Directeur/Membre du Conseil chez BioSight Ltd.
Profil
Gary Gordon is currently a Director at BioSight Ltd.
and also holds Director positions at PhotonPharma, Inc. and Israel Biotech Fund.
Previously, he held Director positions at G.D.
Searle Co. and Abbott Laboratories, as well as Vice President positions at AbbVie, Inc. and OVATION Pharmaceuticals, Inc. He also served as Assistant Professor at The Johns Hopkins University School of Medicine and Chief Medical Officer at Old Ayala, Inc. Gordon received his undergraduate degrees from Stony Brook University and The State University of New York, and his doctorate from The Johns Hopkins University School of Medicine.
Postes actifs de Gary Gordon
| Sociétés | Poste | Début |
|---|---|---|
BioSight Ltd.
 BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Directeur/Membre du Conseil | 18/05/2020 |
PhotonPharma, Inc.
 PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Directeur/Membre du Conseil | - |
Israel Biotech Fund
 Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Consultant / Advisor | - |
Anciens postes connus de Gary Gordon
| Sociétés | Poste | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/04/2018 |
| G.D. Searle Co. | Private Equity Investor | - |
| The Johns Hopkins University School of Medicine | Corporate Officer/Principal | - |
OVATION Pharmaceuticals, Inc.
 OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Directeur Technique/Scientifique/R&D | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Formation de Gary Gordon
| Stony Brook University | Undergraduate Degree |
| The State University of New York | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| ABBVIE INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
OVATION Pharmaceuticals, Inc.
OVATION Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OVATION Pharmaceuticals, Inc. develops, manufactures and markets pharmaceuticals. It focuses on central nervous system, hematology or oncology and hospital-based therapies. The company was founded by Jeffrey S. Aronin in 2000 and is headquartered in Deerfield, IL. | Health Technology |
BioSight Ltd.
BioSight Ltd. Miscellaneous Commercial ServicesCommercial Services BioSight Ltd. is a clinical stage biotechnology company engaging in the development of therapeutics for hematological malignancies and disorders. The company was founded by Stela Gengrinovitchan and Mark Gengrinovitch on November 10, 1999 and is headquartered in Lod, Isreal. | Commercial Services |
Israel Biotech Fund
Israel Biotech Fund Investment ManagersFinance Israel Biotech Fund (Israel Biotech) is a venture capital firm founded in 2015 by Yuval Cabilly, David Sidransky, and Gidon Zairi. The firm is headquartered in Rehovot, Israel. | Finance |
Old Ayala, Inc.
 Old Ayala, Inc. Pharmaceuticals: MajorHealth Technology Old Ayala, Inc. operates as a clinical-stage oncology company. It focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel. | Health Technology |
| G.D. Searle Co. | Commercial Services |
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is developing the Innocell therapeutic cancer vaccine, which is a personalized therapy using autologous tumor tissue. The company is based in Fort Collins, CO at the Research Innovation Center of Colorado State University. The technology is based on a photochemical inactivation platform that uses riboflavin (vitamin B2) and UV light to render tumor cells incapable of replication while still allowing them to metabolize, express proteins, present antigens, and stimulate immune recognition and response mechanisms. In combination with selected adjuvants, Innocell has shown the ability to prevent metastatic tumor formation, reduce tumor growth, and stimulate cellular immune response pathways in preclinical animal models. The company was founded in 2018 by Raymond Goodrich, and Alan S. Rudolph has been the CEO since 2018. | Health Technology |
